<DOC>
	<DOCNO>NCT00844285</DOCNO>
	<brief_summary>The purpose study monitor safety outcomes patient take Cimzia® compare non- Cimzia® control population . The SECURE Registry 's target enrollment 4000 patient 's objective monitor patient approximately 10 year .</brief_summary>
	<brief_title>SECURE , Cimzia ® Crohn 's Disease Post-Marketing Registry</brief_title>
	<detailed_description>Physicians expect manage patient would normal practice condition ; patient receive use medication accord normal course medical treatment .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Patient must medically document Crohn 's disease The decision prescribe Cimzia medication make physician independent inclusion study Patient ( his/her legally acceptable representative ) able provide write informed consent permit collection data Patients participate randomize , blind clinical trial CD condition eligible inclusion SECURE registry . Involvement registry , patient follow routine clinical practice , permit , however For Cimzia cohort : Patient receive treatment Cimzia first time . Patient must receive Cimzia treatment within 2 month enrollment registry Patient currently receive treatment Cimzia ≤12 month . Patient must also receive Cimzia dose within 2 month follow enrollment registry For comparison cohort : Patient switch CD treatment begin CD treatment first time . Previous Cimzia treatment prohibit comparator group . Patient must receive new CD treatment within 2 month enrollment registry . Patient currently receive antiTNF treatment ≤12 month . Patient must receive antiTNF treatment within 2 month follow enrollment registry . Patient currently receive immunosuppressant therapy ≤12 month . Patient must receive immunosuppressant therapy within 2 month follow enrollment registry . Patient currently receive systemic steroid therapy ≤12 month . Patient must receive systemic steroid therapy within 2 month follow enrollment registry See inclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Certolizumab Pegol , Cimzia ®</keyword>
	<keyword>Crohn 's Disease</keyword>
</DOC>